Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States.
dc.contributor.author | Ditkowsky, Jared | |
dc.contributor.author | Shah, Khushal H | |
dc.contributor.author | Hammerschlag, Margaret R | |
dc.contributor.author | Kohlhoff, Stephan | |
dc.contributor.author | Smith-Norowitz, Tamar A | |
dc.date.accessioned | 2023-07-07T16:44:45Z | |
dc.date.available | 2023-07-07T16:44:45Z | |
dc.date.issued | 2017-02-18 | |
dc.identifier.citation | Ditkowsky J, Shah KH, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA. Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States. BMC Infect Dis. 2017 Feb 18;17(1):155. doi: 10.1186/s12879-017-2248-5. PMID: 28214469; PMCID: PMC5316151. | en_US |
dc.identifier.eissn | 1471-2334 | |
dc.identifier.doi | 10.1186/s12879-017-2248-5 | |
dc.identifier.pmid | 28214469 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12648/10401 | |
dc.description.abstract | Chlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) in the United States (U.S.) [1] and remains a major public health problem. We determined the cost- benefit of screening all pregnant women aged 15-24 for Chlamydia trachomatis infection compared with no screening. | |
dc.description.abstract | We developed a decision analysis model to estimate costs and health-related effects of screening pregnant women for C. trachomatis in a high burden setting (Brooklyn, NY). Outcome data was from literature for pregnant women in the 2015 US population. A virtual cohort of 6,444,686 pregnant women, followed for 1 year was utilized. Using outcomes data from the literature, we predicted the number of C. trachomatis cases, associated morbidity, and related costs. Two comparison arms were developed: pregnant women who received chlamydia screening, and those who did not. Costs and morbidity of a pregnant woman-infant pair with C. trachomatis were calculated and compared. | |
dc.description.abstract | Cost and benefit of screening relied on the prevalence of C. trachomatis; when rates are above 16.9%, screening was proven to offer net cost savings. At a pre-screening era prevalence of 8%, a screening program has an increased expense of $124.65 million ($19.34/individual), with 328 thousand more cases of chlamydia treated, and significant reduction in morbidity. At a current estimate of prevalence, 6.7%, net expenditure for screening is $249.08 million ($38.65/individual), with 204.63 thousand cases of treated chlamydia and reduced morbidity. | |
dc.description.abstract | Considering a high prevalence region, prenatal screening for C. trachomatis resulted in increased expenditure, with a significant reduction in morbidity to woman-infant pairs. Screening programs are appropriate if the cost per individual is deemed acceptable to prevent the morbidity associated with C. trachomatis. | |
dc.language.iso | en | en_US |
dc.relation.url | https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2248-5 | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | C. trachomatis | en_US |
dc.subject | Chlamydia screening | en_US |
dc.subject | Pregnant women | en_US |
dc.title | Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States. | en_US |
dc.type | Article/Review | en_US |
dc.source.journaltitle | BMC infectious diseases | en_US |
dc.source.volume | 17 | |
dc.source.issue | 1 | |
dc.source.beginpage | 155 | |
dc.source.endpage | ||
dc.source.country | England | |
dc.description.version | VoR | en_US |
refterms.dateFOA | 2023-07-07T16:44:45Z | |
html.description.abstract | Chlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) in the United States (U.S.) [1] and remains a major public health problem. We determined the cost- benefit of screening all pregnant women aged 15-24 for Chlamydia trachomatis infection compared with no screening. | |
html.description.abstract | We developed a decision analysis model to estimate costs and health-related effects of screening pregnant women for C. trachomatis in a high burden setting (Brooklyn, NY). Outcome data was from literature for pregnant women in the 2015 US population. A virtual cohort of 6,444,686 pregnant women, followed for 1 year was utilized. Using outcomes data from the literature, we predicted the number of C. trachomatis cases, associated morbidity, and related costs. Two comparison arms were developed: pregnant women who received chlamydia screening, and those who did not. Costs and morbidity of a pregnant woman-infant pair with C. trachomatis were calculated and compared. | |
html.description.abstract | Cost and benefit of screening relied on the prevalence of C. trachomatis; when rates are above 16.9%, screening was proven to offer net cost savings. At a pre-screening era prevalence of 8%, a screening program has an increased expense of $124.65 million ($19.34/individual), with 328 thousand more cases of chlamydia treated, and significant reduction in morbidity. At a current estimate of prevalence, 6.7%, net expenditure for screening is $249.08 million ($38.65/individual), with 204.63 thousand cases of treated chlamydia and reduced morbidity. | |
html.description.abstract | Considering a high prevalence region, prenatal screening for C. trachomatis resulted in increased expenditure, with a significant reduction in morbidity to woman-infant pairs. Screening programs are appropriate if the cost per individual is deemed acceptable to prevent the morbidity associated with C. trachomatis. | |
dc.description.institution | SUNY Downstate | en_US |
dc.description.department | Pediatrics | en_US |
dc.description.degreelevel | N/A | en_US |
dc.identifier.journal | BMC infectious diseases | |
dc.identifier.issue | 1 | en_US |